MOYA Bio
Ness Ziona
About MOYA Bio
MOYA Bio is developing novel E1 inhibitors for solid and hematological malignancies. The company's unique drugs are designed to target and selectively modify the Ubiquitin and Ubiquitin-Like (UBL) pathways, resulting in direct anti-tumor actions while also enhancing the effectiveness of other therapeutic methods.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Funding stage: Seed
- Last round: Seed (Jan 2019)
- Phone: [email protected]
Industries & Categories
Biopharma, Biotechnology, Therapeutics
Canonical: https://fsome.com/organization/moya-bio-3754028 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.